瑞银:上调Nuvalent(NUVL.US)评级,由中性调整至买入评级,目标价由100.00美元调整至100.00美元。Nuvalent(NUVL.US)公司简介:Nuvalent,Inc.是一家临床阶段的生物制药公司,专注于为癌症患者创造精确靶向治疗。其产品线包括ROS1NSCLC、ALK NSCLC和HER2NSCLC。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.